查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1961064

全球外泌体研究市场：依产品/服务、适应症、应用、终端用户和地区划分－市场动态、市场分析、机会和预测（2026-2035 年）

Global Exosome Research Market: By Product & Service, Indication, Application, End User, Region - Market Dynamics, Market Analysis, Opportunity Forecasted For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 242 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录
外泌体研究市场正处于关键的转折点，其特征是快速成长和不断扩大的商业潜力。 2025 年，该市场规模约为 2.807 亿美元，预计将显着成长，到 2035 年营收将达到 24.9142 亿美元。这一显着增长反映了 2026 年至 2035 年预测期内 24.4% 的复合年增长率，凸显了外泌体技术在研究和治疗领域日益增长的重要性和应用。 推动这一转变的关键因素之一是已证实临床疗效数据的积累，这增强了外泌体作为有效治疗剂的可信度。随着越来越多的临床试验证实了基于外泌体的疗法的安全性和治疗益处，包括製药公司、投资者和监管机构在内的利益相关者日益认识到其在满足未被满足的医疗需求方面的潜力。同时，可扩展生产技术的进步使得生产数量和品质均符合广泛商业化分销要求的外泌体成为可能。

主要市场趋势

外泌体研究市场的竞争格局清晰地分为两大类：治疗先驱者和产业基础设施开发商，两者都在该领域的发展中发挥着至关重要的作用。在治疗领域，Capricor Therapeutics 和 Direct Biologics 无疑是业界领导者。 Capricor Therapeutics 的策略优势源自于其雄厚的财务实力，截至 2025 年，该公司拥有 1.52 亿美元的现金储备。如此强劲的财务状况确保了公司拥有必要的资源来支持基于外泌体的疗法的开发和商业化。

同时，Direct Biologics凭藉其卓越的临床进展建立了竞争优势，包括在其III期主要试验 "EXTINGUISH" 中成功招募了320名患者。此外，该公司还实施了扩大用药计划，为103名患者提供了治疗，展现了在推动临床开发和确保患者用药之间取得的显着平衡。

在基础设施方面，Lonza和Bio-Techne作为支撑外泌体研究生态系统的关键产业基础，发挥主导作用。特别是，Lonza已积极确立其作为外泌体治疗领域领先的合约开发和生产组织（CDMO）的地位。 Lonza 扩张过程中的一个重要里程碑是收购了 Codiak BioSciences 的外泌体生产设施（位于马萨诸塞州莱剋星顿），该收购于 2021 年 11 月完成。

核心驱动因素

目前，外泌体研究市场由两大强劲的需求引擎驱动，它们正在重塑市场发展轨迹并推动快速创新。一方面，对非侵入性 "液体活检" 生物标誌物的需求迫切且日益增长。这为临床医生提供了一种创新的疾病诊断和监测方法，只需简单的血液检测和其他体液样本即可。与传统的侵入性、高成本且耗时的活检不同，液体活检利用外泌体携带的独特分子特征，能够早期且高精度地检测疾病状况。这种能力在肿瘤学领域尤其重要，因为癌症的早期发现可以显着改善患者的预后。

新兴机会趋势

影响外泌体研究市场的最重要趋势之一是工作流程的日益工业化。这标誌着从手动实验室技术转向标准化自动化流程的重大转变。传统上，外泌体分离被认为是一种“技术”，依赖于劳动密集的手工方法，需要专业知识，并且常常导致批次间差异。如今，这种方法正迅速被高度可重复且可扩展的工作流程所取代，这些工作流程旨在满足临床研究和商业生产的严格要求。这种转变清晰地体现在高通量流式细胞仪技术的日益普及上，该技术能够以更高的准确性和效率对外泌体群体进行快速、详细的分析。

优化障碍

缺乏普遍接受的纯化外泌体 "黄金标准" 是外泌体研究市场的一大挑战，促使不同分离方法的产量、纯度和污染水平有显着差异。缺乏标准化使得製备稳定可靠的外泌体变得复杂，而外泌体对于研究应用和治疗产品开发都至关重要。在常用的技术中，超速离心法因其能够根据密度和大小分离外泌体，长期以来被视为一种基础方法。

目录

第一章：研究架构

  • 研究目标
  • 产品概述
  • 市场区隔

第二章：研究方法

  • 质性研究
    • 一手和二手资料
  • 量化研究
    • 一手和二手资料
  • 依地区划分的原始调查受访者
  • 本研究的假设
  • 市场规模估算
  • 资料三角验证

第三章：摘要整理：全球外泌体研究市场

第四章：全球外泌体研究市场概论

  • 产业价值链分析
    • 原料供应商
    • 製造商
    • 经销商
    • 终端用户
  • 行业展望
    • 全球外泌体CDMO业务
    • 外泌体作为新型态疗法的新兴作用
  • PESTLE分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场动态与趋势
    • 成长因素
    • 限制因素
    • 机遇
    • 关键因素趋势
  • COVID-19 对市场成长趋势的影响评估
  • 市场成长与展望
    • 市场收入估计与预测（2020-2035 年）
  • 竞争格局概览
    • 市场集中度
    • 公司占有率分析（基于价值，2025 年）
    • 竞争格局图

第五章 全球外泌体研究市场分析：依产品与服务划分

  • 主要发现
  • 市场规模及预测（2020-2035 年）
    • 试剂盒和试剂
    • 设备
    • 服务

第六章 全球外泌体研究市场分析：依适应症

  • 主要观点
  • 市场规模及预测（2020–2035）
    • 癌症
    • 非癌症

第7章 全球胞外体调查市场分析:各用途

  • 主要的见解
  • 市场规模与预测，2020年～2035年
    • 生物标记
    • 疫苗开发
    • 药物输送
    • 化妆品用途
    • 组织再生
    • 其他

第八章 全球外泌体研究市场分析：依最终使用者划分

  • 主要观点
  • 市场规模及预测（2020–2035）
    • 学术以及研究机构
    • 製药和生技公司
    • 医院和临床实验室

第九章 全球外泌体研究市场分析：依地区划分

  • 主要的见解
  • 市场规模与预测(2020年～2035年)
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第十章：北美外泌体研究市场分析

第十一章：欧洲外泌体研究市场分析

第十二章：亚太地区外泌体研究市场分析

第十三章：中东与非洲外泌体研究市场分析

第14章 南美的胞外体调查市场分析

第15章 美国的胞外体调查市场分析

第16章 中国的胞外体调查市场分析

第17章 日本的胞外体调查市场分析

第18章 企业简介

  • AMS Biotechnology(Europe)Ltd.
  • Bio-Techne Corporation
  • Lonza
  • Miltenyi Biotec
  • NanoSomiX, Inc.
  • Norgen Biotek Corp.
  • Novus Biologicals
  • NX PharmaGen
  • QIAGEN
  • System Biosciences, LLC
  • Thermo Fisher Scientific, Inc.
  • Other prominent players.
简介目录
Product Code: AA0223361

The exosome research market is undergoing a significant and definitive pivot, marked by rapid growth and expanding commercial potential. Valued at approximately US$ 280.70 million in 2025, the market is projected to experience remarkable expansion, with revenues anticipated to reach US$ 2,491.42 million by 2035. This impressive growth reflects a compound annual growth rate (CAGR) of 24.4% over the forecast period from 2026 to 2035, underscoring the increasing importance and adoption of exosome technologies across research and therapeutic domains.

One of the primary forces propelling this transformation is the accumulation of validated clinical efficacy data, which strengthens confidence in exosomes as effective therapeutic agents. As more clinical trials demonstrate the safety and therapeutic benefits of exosome-based treatments, stakeholders-including pharmaceutical companies, investors, and regulatory authorities-are increasingly recognizing their potential to address unmet medical needs. Coupled with this clinical validation is the advancement of scalable manufacturing technologies, enabling the production of exosomes in quantities and quality suitable for widespread commercial distribution.

Noteworthy Market Developments

The competitive landscape in the exosome research market is distinctly divided between two key groups: therapeutic pioneers and industrial enablers, each playing a critical role in advancing the field. On the therapeutic front, Capricor Therapeutics and Direct Biologics stand out as the undisputed leaders. Capricor Therapeutics' strategic strength is underscored by its solid financial foundation, boasting a robust cash balance of USD 152 million as it entered 2025. This strong financial position equips Capricor with the necessary resources to support the development and commercialization of its exosome-based therapies.

Meanwhile, Direct Biologics has cemented its dominance through impressive clinical progress, managing a substantial enrollment of 320 patients in their pivotal Phase 3 EXTINGUISH trial. Additionally, Direct Biologics has operated an Expanded Access Program, providing treatment to 103 patients, which highlights the company's commitment to both clinical advancement and patient access.

On the infrastructure side, Lonza and Bio-Techne are setting the pace as essential industrial enablers supporting the exosome research ecosystem. Lonza, in particular, has aggressively established itself as the premier contract development and manufacturing organization (CDMO) for exosome therapeutics. A significant milestone in Lonza's expansion was the acquisition of Codiak BioSciences' exosome manufacturing facility in Lexington, Massachusetts, completed in November 2021.

Core Growth Drivers

The exosome research market is currently propelled by a powerful dual-engine demand that is reshaping its trajectory and driving rapid innovation. On one hand, there is an urgent and growing need for non-invasive "liquid biopsy" biomarkers, which provide clinicians with a revolutionary means of diagnosing and monitoring diseases through simple blood tests or other bodily fluids. Unlike traditional biopsies, which are often invasive, costly, and time-consuming, liquid biopsies harness the unique molecular signatures carried by exosomes to detect disease states early and with high precision. This capability is particularly valuable in oncology, where early detection of cancer can significantly improve patient outcomes.

Emerging Opportunity Trends

One of the most critical trends shaping the exosome research market is the ongoing industrialization of the workflow, marking a profound transformation from artisanal laboratory techniques to standardized, automated engineering processes. Historically, isolating exosomes was considered more of an "art," reliant on manual, labor-intensive methods that required significant expertise and often resulted in variability between batches. Today, this approach is rapidly being replaced by highly reproducible, scalable workflows designed to meet the stringent demands of both clinical research and commercial manufacturing. This shift is clearly evident in the growing adoption of high-throughput flow cytometry technologies, which enable rapid, detailed analysis of exosome populations with increased accuracy and efficiency.

Barriers to Optimization

The absence of a universally accepted "gold standard" for isolating pure exosomes presents a significant challenge within the exosome research market, contributing to considerable variability in yield, purity, and contamination levels across different isolation methods. This lack of standardization complicates efforts to produce consistent and reliable exosome preparations, which are critical for both research applications and the development of therapeutic products. Among the commonly used techniques, ultracentrifugation has long been considered a foundational method due to its ability to separate exosomes based on density and size.

Detailed Market Segmentation

By Product & Services, by 2025, the exosome research market has matured significantly, prompting a decisive shift away from basic, rudimentary precipitation methods toward more advanced and high-purity isolation technologies. This transition reflects the increasing complexity and rigor required in exosome research, especially as the market moves toward clinical and therapeutic applications where product consistency and purity are paramount. The Kits and Reagents segment has maintained its dominant position within the market, capturing a substantial 45.1% share of total revenue.

By Indication, cancer research remains the foundational pillar anchoring the exosome research market, with the oncology segment expected to capture approximately 34.3% of the total market share in 2025. This dominant position reflects the intense focus within the scientific and medical communities on leveraging exosomes to understand, diagnose, and treat various forms of cancer. Exosomes have proven to be invaluable in oncology, particularly as biomarkers that can provide critical insights into tumor biology, disease progression, and treatment response. This steady demand underscores the profound need for innovative tools and therapies capable of addressing the complex challenges posed by cancer.

By End Users, the balance of power in market consumption within the exosome research market has decisively shifted toward the commercial sector, marking a significant change in the dynamics of end-user engagement. By 2025, Pharmaceutical and Biotechnology Companies had emerged as the dominant purchasers, commanding a substantial 49.1% share of the market. This marked overtaking of academic institutions, which historically led demand for exosome research tools and services, reflects a broader trend towards the industrialization and commercialization of exosome technologies.

By Application, while diagnostic applications in the exosome research market continue to generate substantial transaction volumes, the overall value proposition has increasingly shifted toward therapeutic development. In 2025, this shift is particularly evident in the biomarker application segment, which is forecasted to capture over 49.40% of the market share, significantly outperforming the broader market trend. This growth highlights the escalating importance of exosomes as powerful tools not only for disease detection but also for revolutionizing treatment approaches. The biomarker segment's expansion reflects growing confidence in the ability of exosomes to provide highly sensitive and specific indicators of disease states, enabling earlier diagnosis and personalized medicine strategies across a range of medical conditions.

Segment Breakdown

By Product Type

  • Kits & Reagents
  • Antibodies
  • Isolation, Purification, Quantitation Kits & Reagents
  • Other Kits & Reagents
  • Instruments
  • Services

By Indication

  • Cancer
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Other Cancers
  • Non-Cancer
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Others

By Application

  • Biomarkers
  • Vaccine Development
  • Drug delivery
  • Cosmetic Application
  • Tissue Regeneration
  • Other

By End User

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • CDMO
  • Biopharma
  • Hospital & Clinical Testing Laboratories

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Poland
  • Russia
  • Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
  • South America
  • Brazil
  • Argentina
  • Rest of South America

Geography Breakdown

  • North America currently commands an impressive 53.10% share of the global exosome research market, a dominance that reflects a uniquely synchronized regulatory and financial ecosystem that few competitors worldwide can rival. This leadership position is not merely the result of scientific expertise or technological innovation but stems from a well-coordinated framework where regulatory agencies and capital markets work in tandem to accelerate the development and commercialization of exosome-based therapies. The U.S. Food and Drug Administration (FDA) plays a pivotal role in shaping this environment by providing clear regulatory pathways and predictable timelines, which in turn reduce uncertainty for developers and investors.
  • Complementing the regulatory support is the availability of immense financial liquidity within North American capital markets, which provides the substantial funding necessary to sustain the costly and lengthy process of drug development. Capricor Therapeutics exemplifies this financial strength, reporting a robust cash balance of USD 152 million dedicated to supporting its research pipeline. This level of funding enables companies to invest heavily in clinical trials, manufacturing capacity, and commercialization efforts without the immediate pressure of capital constraints.

Leading Market Participants

  • AMS Biotechnology (Europe) Ltd.
  • Bio-Techne Corporation
  • Lonza
  • Miltenyi Biotec
  • NanoSomiX, Inc.
  • Norgen Biotek Corp.
  • Novus Biologicals
  • NX PharmaGen
  • QIAGEN
  • System Biosciences, LLC
  • Thermo Fisher Scientific, Inc.
  • Other prominent players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Exosome Research Market

Chapter 4. Global Exosome Research Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Exosome CDMO Business around the World
    • 4.2.2. The emerging role of exosomes as novel therapeutics
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Opportunity
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2035
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2025
    • 4.8.3. Competitor Mapping

Chapter 5. Global Exosome Research Market Analysis, By Product & Service

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 5.2.1. Kits & Reagents
      • 5.2.1.1. Antibodies
      • 5.2.1.2. Isolation, Purification, Quantitation Kits & Reagents
      • 5.2.1.3. Other Kits & Reagents
    • 5.2.2. Instruments
    • 5.2.3. Services

Chapter 6. Global Exosome Research Market Analysis, By Indication

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 6.2.1. Cancer
      • 6.2.1.1. Lung Cancer
      • 6.2.1.2. Breast Cancer
      • 6.2.1.3. Prostate Cancer
      • 6.2.1.4. Colorectal Cancer
      • 6.2.1.5. Other Cancers
    • 6.2.2. Non-Cancer
      • 6.2.2.1. Neurodegenerative Diseases
      • 6.2.2.2. Cardiovascular Diseases
      • 6.2.2.3. Infectious Diseases
      • 6.2.2.4. Others

Chapter 7. Global Exosome Research Market Analysis, By Application

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 7.2.1. Biomarkers
    • 7.2.2. Vaccine Development
    • 7.2.3. Drug delivery
    • 7.2.4. Cosmetic Application
    • 7.2.5. Tissue Regeneration
    • 7.2.6. Other

Chapter 8. Global Exosome Research Market Analysis, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 8.2.1. Academic & Research Institutes
    • 8.2.2. Pharmaceutical & Biotechnology Companies
      • 8.2.2.1. CDMO
      • 8.2.2.2. Biopharma
    • 8.2.3. Hospital & Clinical Testing Laboratories

Chapter 9. Global Exosome Research Market Analysis, By Region

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 9.2.1. North America
      • 9.2.1.1. The U.S.
      • 9.2.1.2. Canada
      • 9.2.1.3. Mexico
    • 9.2.2. Europe
      • 9.2.2.1. Western Europe
        • 9.2.2.1.1. The UK
        • 9.2.2.1.2. Germany
        • 9.2.2.1.3. France
        • 9.2.2.1.4. Italy
        • 9.2.2.1.5. Spain
        • 9.2.2.1.6. Rest of Western Europe
      • 9.2.2.2. Eastern Europe
        • 9.2.2.2.1. Poland
        • 9.2.2.2.2. Russia
        • 9.2.2.2.3. Rest of Eastern Europe
    • 9.2.3. Asia Pacific
      • 9.2.3.1. China
      • 9.2.3.2. India
      • 9.2.3.3. Japan
      • 9.2.3.4. South Korea
      • 9.2.3.5. Australia & New Zealand
      • 9.2.3.6. ASEAN
      • 9.2.3.7. Rest of Asia Pacific
    • 9.2.4. Middle East & Africa
      • 9.2.4.1. UAE
      • 9.2.4.2. Saudi Arabia
      • 9.2.4.3. South Africa
      • 9.2.4.4. Rest of MEA
    • 9.2.5. South America
      • 9.2.5.1. Argentina
      • 9.2.5.2. Brazil
      • 9.2.5.3. Rest of South America

Chapter 10. North America Exosome Research Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 10.2.1. By Product & Service
    • 10.2.2. By Indication
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country

Chapter 11. Europe Exosome Research Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 11.2.1. By Product & Service
    • 11.2.2. By Indication
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Country

Chapter 12. Asia Pacific Exosome Research Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 12.2.1. By Product & Service
    • 12.2.2. By Indication
    • 12.2.3. By Application
    • 12.2.4. By End User
    • 12.2.5. By Country

Chapter 13. Middle East and Africa Exosome Research Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 13.2.1. By Product & Service
    • 13.2.2. By Indication
    • 13.2.3. By Application
    • 13.2.4. By End User
    • 13.2.5. By Country

Chapter 14. South America Exosome Research Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 14.2.1. By Product & Service
    • 14.2.2. By Indication
    • 14.2.3. By Application
    • 14.2.4. By End User
    • 14.2.5. By Country

Chapter 15. The U.S Exosome Research Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 15.2.1. By Product & Service
    • 15.2.2. By Indication
    • 15.2.3. By Application
    • 15.2.4. By End User

Chapter 16. China Exosome Research Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 16.2.1. By Product & Service
    • 16.2.2. By Indication
    • 16.2.3. By Application
    • 16.2.4. By End User

Chapter 17. Japan Exosome Research Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 17.2.1. By Product & Service
    • 17.2.2. By Indication
    • 17.2.3. By Application
    • 17.2.4. By End User

Chapter 18. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 18.1. AMS Biotechnology (Europe) Ltd.
  • 18.2. Bio-Techne Corporation
  • 18.3. Lonza
  • 18.4. Miltenyi Biotec
  • 18.5. NanoSomiX, Inc.
  • 18.6. Norgen Biotek Corp.
  • 18.7. Novus Biologicals
  • 18.8. NX PharmaGen
  • 18.9. QIAGEN
  • 18.10. System Biosciences, LLC
  • 18.11. Thermo Fisher Scientific, Inc.
  • 18.12. Other prominent players.